


XEN-45 implant effective in uncontrolled uveitic glaucoma

29 October 2017



"The XEN-45 [implant](#) is effective for the treatment of patients with medically uncontrolled uveitic [glaucoma](#). Potentially sight-threatening complications, including bleb-related ocular infection and persistent hypotony, may occur," the authors write.

Two authors disclosed financial ties to Allergan, which manufactures XEN-45, and one disclosed ties to Aquesys, an Allergan affiliate.

More information: [Abstract](#)
[Full Text \(subscription or payment may be required\)](#)

Copyright © 2017 [HealthDay](#). All rights reserved.

(HealthDay)—For medically uncontrolled uveitic glaucoma, the XEN-45 implant is effective, reducing the need for further surgery, according to a study published online Oct. 20 in *Clinical & Experimental Ophthalmology*.

Chelvin C.A. Sng, from Moorfields Eye Hospital in London, and colleagues examined the safety and efficacy of the XEN-45 collagen implant in eyes with uveitic glaucoma in an exploratory prospective case series. Participants included 24 [patients](#) with medically uncontrolled uveitic glaucoma who were implanted with XEN-45.

The researchers found that after implantation of XEN-45, further surgery was not needed in the 20 eyes in whom conventional glaucoma [surgery](#) was thought to be inevitable. There were reductions in the mean intraocular pressure (from 30.5 ± 9.8 to 12.2 ± 3.1 mmHg) and in the mean number of medications required (from 3.3 ± 0.8 to 0.4 ± 0.9) from baseline to 12 months (both P

APA citation: XEN-45 implant effective in uncontrolled uveitic glaucoma (2017, October 29) retrieved 27 August 2022 from

<https://medicalxpress.com/news/2017-10-xen-implant-effective-uncontrolled-uveitic.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.